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Aim To replicate the genome-wide associations of the antihypertensive effects of 
bisoprolol and losartan in GENRES, using the Finnish patients of LIFE study. Patients 
& methods: We analyzed association of four SNPs with atenolol and three SNPs with 
losartan response in 927 Finnish LIFE patients (467 for atenolol and 460 for losartan). 
Results: rs2514036, a variation at a transcription start site of ACY3, was associated 
with blood pressure response to atenolol in men in LIFE. Response to bisoprolol was 
correlated to baseline plasma levels of N-acetylphenylalanine and phenylalanine (ACY3 
substrate and end product, respectively) in GENRES study. NPHS1 variation rs3814995 
was associated with losartan effect in LIFE. Conclusion: We provide support for two 
pharmacogenomic markers for beta-blockers and angiotensin receptor antagonists. 
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In the past few decades, hypertension has 
become the leading risk factor for global dis-
ease burden through its contribution to car-
diovascular morbidity and mortality, as well 
as total mortality [1]. By effective drug treat-
ment of hypertension it is possible to decrease 
the amount of cardiovascular events to the 
extent closely paralleling the blood pressure 
(BP) response achieved [2]. On average, the 
main groups of antihypertensive agents are 
equally effective on lowering BP, but there 
is a wide variation in individual antihyper-
tensive drug responsiveness [3]. The different 
antihypertensive drugs are not equal in their 
efficacy in preventing specific cardiovascular 
outcomes [2], and many international guide-
lines for hypertension therapy recommend 
medication to be chosen based on coexisting 
conditions [4]. It is frustrating that despite 
the wide selection of antihypertensive drugs 
available, only 40–50% of hypertensive 
patients seem to achieve adequate BP control 
while on drug therapy [5].
Genomic differences are proposed to 
constitute one of the factors explaining the 
individual variation of BP responses to drug 
treatment [6–8]. Searches for genetic vari-
ants associating with antihypertensive drug 
therapies have evolved from candidate gene 
studies to genome-wide association studies 
(GWAS), with moderate success [6–11]. Most 
studies have suffered from methodological or 
analy tical problems, including an insufficient 
sample size, lack of blinding, use of office BP 
measure ments only and limited use of replica-
tion materials. It is possible that population 
differences may explain some of the failed 
attempts to replicate certain genomic asso-
ciations to antihypertensive drug respon-
siveness [7], which may justify use of patient 
cohorts coming from genetically more 
 homogeneous populations.
To diminish possible influence of the 
genetic admixture of the study popula-
tion [12], we decided to replicate the results of 
our previous pharmacogenomic three-stage 
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GWAS (GENRES study) [10] in Finnish participants to 
another antihypertensive drug study (LIFE) [13]. Of the 
four classes of drugs used in GENRES (beta-blocker, 
diuretic, calcium channel blocker and angiotensin II 
type 1 receptor antagonist), we were able to replicate 
data on beta-blocker (bisoprolol in GENRES, atenolol 
in LIFE) and angiotensin receptor antagonist (losartan 
in both GENRES and LIFE). As the variants to be rep-
licated in LIFE, we chose the SNPs showing the stron-
gest associations, as also supported by replication data 
in the Italian and US populations, with BP response 
to bisoprolol (rs2514036, rs7984003, rs7268800 and 
rs2765115) and losartan (rs3814995, rs4953045 and 
rs12814605) in 228 hypertensive  Finnish men [10].
Patients & methods
Short description of the GENRES study
The GENRES study is the only randomized, double- 
blind, cross-over, placebo-controlled pharmaco genomic 
study in which four classes of antihypertensive drugs 
(a diuretic, beta-blocker, calcium channel blocker and 
angiotensin receptor antagonist), each as a mono-
therapy, were studied in a rotational fashion, using both 
office and ambulatory BP recordings [10,14]. The study 
was completed in 228 Finnish men. The performance 
of the GENRES platform was validated, for example, 
by pairwise correlations of antihypertensive responses 
of different antihypertensive drug classes and corre-
lations of baseline plasma renin activities to individual 
drug responses [14,15]. A recent GWAS of GENRES 
revealed three SNPs in the same locus associating with a 
specific drug response with a genome-wide significance 
(p < 5 × 10-8) and 39 SNPs in 30 different loci with a 
suggestive significance (p < 1 × 10-5) [10].
LIFE study
The LIFE study design and main findings have been 
described elsewhere [13]. In brief, LIFE was a prospective 
multicenter (Scandinavia, UK, USA), double-blind, 
double-dummy, randomized, active-controlled study 
that was designed to evaluate the long-term effects of 
losartan compared with atenolol in 9193 hypertensive 
patients with signs of left ventricle hypertrophy (LVH) 
in ECG. Patients aged 55–80 with office systolic BP 
(SBP) of 160–200 mmHg or diastolic BP (DBP) of 
95–115 mmHg and signs of LVH in ECG were eligible 
to participate in the study. After withdrawal of all anti-
hypertensive drugs and 2 weeks on placebo treatment, 
the study subjects were randomized to receive either 
losartan- or atenolol-based antihypertensive regimen. 
Target BP was 140/90 mmHg or lower, and the anti-
hypertensive medication was titrated according to the 
study scheme to achieve the goal. Initially, the treat-
ment consisted of either 50 mg of losartan or 50 mg of 
atenolol. If the BP target was not reached, 12.5 mg of 
hydrochlorothiazide was added. If needed, the dosage 
of the study drug was escalated to 100 mg and last the 
dosage of hydrochlorothiazide was escalated to 25 mg, 
or other antihypertensive agents were added. The study 
subjects were followed for a mean of 4.8 years for the 
primary end points of stroke, myocardial infarction 
and cardiovascular death. A prespecified pharmaco-
genetic substudy [16] was conducted among 3503 Scan-
dinavian participants of the LIFE study to test whether 
candidate gene polymorphisms affected BP or heart 
rate reduction, cardiovascular events or response to 
treatment. The 1146 Finnish participants of the LIFE 
pharmacogenetic sample were available for the pres-
ent study. The main treatment protocol of the LIFE 
study and the protocol of the genetics substudy were 
approved by local ethical committees, and all partici-
pants gave a written informed consent. Office BP and 
drug treatment data were recorded at baseline and at 
2, 4 and 6 months after the beginning of the treat-
ment and later on at 6-month intervals. To achieve 
resemblance to the design of the GENRES study, we 
focused on BP responses at 2 months in patients who 
were using monotherapy of 50 mg of atenolol or 50 mg 
of losartan, or a combination therapy of either of them 
plus 12.5 mg of hydrochlorothiazide.
Genotyping
The DNA samples of 1146 LIFE study subjects were 
genotyped at the Institute for Molecular Medicine 
Finland, University of Helsinki (FIMM) using the 
Illumina HumanOmniExpress BeadChip® (Illumina, 
CA, USA), the same platform as used in the GENRES 
study [10]. Quality control was performed for the data 
obtained, and 69 patients were excluded because of 
low success rates (<95%), discrepancy in gender check 
or demonstration of first-degree relativeness. An addi-
tional 116 patients, who at the 2-month visit were not 
using monotherapy of 50 mg of the study drug, or a 
combination therapy of either plus 12.5 mg of hydro-
chlorothiazide, were excluded from the present analy-
ses. Furthermore, 34 patients, who were either morbidly 
obese (BMI >40), had stage four chronic kidney dis-
ease (glomerular filtration rate <30 ml/min/1.73 m2, or 
urine microalbumin >300 mg/l) or had a BP response 
residual deviating more than four standard deviations 
from the mean, were excluded from the analyses. The 
genotypes of the SNPs used in this study were tested 
for Hardy–Weinberg equilibrium and no deviation was 
observed.
Metabolomic measurements
The metabolomic analysis was performed in EDTA 
plasma from 35 GENRES patients who had completed 
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the whole four-drug study, and who had complete 
ambulatory 24-h BP response data to bisoprolol, with 
>600 known metabolites measured across diverse and 
broadly defined biochemical classes including amino 
acids and peptides (171 biochemicals), carbohydrates 
(20 biochemicals), energy/tricarboxylic acid cycle 
intermediates (eight biochemicals), lipids (260 bio-
chemicals), nucleotides (27 biochemicals), vitamins 
and cofactors (25 biochemicals) and xenobiotics 
(106 biochemicals). Thus, the results presented here 
are based on 175 plasma samples, four from placebo 
and one from bisoprolol periods for each patient.
Nontargeted mass spectrometry (MS) analysis was 
performed at Metabolon, Inc. (NC, USA). EDTA-
anticoagulated plasma samples were stored at -80°C 
until processed. Sample preparation and metabolite 
extraction were carried out as described previously [17]. 
The metabolites were identified and quantified using 
ultra high-performance LC–MS/MS [18,19]. A detailed 
description of the metabolomic analysis is provided in 
the Supplementary Methods.
Statistical analysis
The baseline demographics and BP responses of the 
study subjects were analyzed using IBM SPSS Statis-
tics 22.0. Fisher’s exact test and Student’s t-test were 
used to compare the clinical characteristics of the 
GENRES and the LIFE study subgroups. A statistical 
approach similar to the discovery GWAS (GENRES 
study) was used to test the SNP associations in 
LIFE [10]. SBP and DBP response residuals were gen-
erated separately for both atenolol and losartan using 
linear regression adjusting for age, sex, baseline BP, 
BMI and use of hydrochlorothiazide at 2 months 
(Supplementary Table 1). In the second step, current 
smoking and serum creatinine were tested using step-
wise regression and included if significant (p < 0.10). 
In the LIFE study, covariate-adjusted atenolol BP 
response residuals were analyzed for associations with 
the four bisoprolol-associated SNPs derived from the 
GENRES GWAS, using the linear regression and addi-
tive genetic model in PLINK v1.07 [20], and likewise 
covariate-adjusted losartan residuals were analyzed for 
associations with the three losartan-associated SNPs 
derived from the GENRES study. The rationale for 
the selection of SNPs for the current study is described 
in Supplementary Table 2. Because the study subjects of 
the discovery GWAS were all men, a separate associa-
tion analysis was performed in men if SNP × sex inter-
action was significant (p < 0.05). As there was previous 
evidence for the associations, successful replication was 
defined as p < 0.05 with effect in the same direction 
as in the initial study. A more conservative approach, 
using Bonferroni correction, would have required a 
nominal two-sided p-value of 0.014 (= 0.05/7 × 2), 
based on seven SNPs and requirement of same direc-
tion of effect and taking into account the fact that 
 systolic and diastolic responses are highly correlated.
Power calculations for the genetic replication analy-
ses of the seven SNPs in LIFE were carried out using 
program Quanto, v. 1.2.4 [21]. The power estimates 
for reaching two-sided p-values of <0.05 and β-values 
obtained in GENRES ranged from 56 to 99% 
(Supplementary Table 3).
In the metabolomic analyses of the GENRES 
patients, normalized values of metabolite concentra-
tions were used. The mean level of four placebo periods 
was used as the baseline level (a similar approach was 
used for the BP data in GENRES). For Pearson cor-
relation analyses of metabolite baseline levels with pla-
cebo BP levels and bisoprolol BP responses, covariate-
adjusted residuals were generated; the tested variables 
in stepwise regression were age, BMI, current smoking, 
serum creatinine, fasting serum glucose and daily uri-
nary sodium excretion after the first placebo period of 
the study. Using p < 0.10 as a criterion, serum creati-
nine was selected as a covariate for plasma phenylala-
nine concentration (standardized β = 0.37; p = 0.02), 
daily urinary sodium excretion for N-acetylphenyl-
alanine (standardized β = -0.36; p = 0.03) and fast-
ing serum glucose for N-acetyltyrosine (standardized 
β = 0.35; p = 0.03). None of the tested variables was 
significant for plasma tyrosine concentration. In the 
correlation analyses, residuals were also used for pla-
cebo BP levels and bisoprolol BP responses. They were 
generated, correspondingly, using the whole GENRES 
population. Age and serum creatinine were used as 
covariates for placebo ambulatory SBP level, but none 
was significant for placebo DBP level. Placebo baseline 
SBP level and current smoking were used as covariates 
for bisoprolol SBP response and placebo DBP level for 
bisoprolol DBP response, as described previously [10]. 
Bisoprolol-induced metabolite concentration changes 
were analyzed with paired t-test.
Results
Study subjects
A detailed description of the study subjects of the 
GENRES study is given in our previous publica-
tions [10,14,15]. The main characteristics are also listed 
in Table 1.
Clinical characteristics of the LIFE study subgroups 
are described in Table 1. A total of 927 Finnish men 
and women were included in the genetic analysis of the 
present study; 467 in the atenolol group and 460 in the 
losartan group. The baseline characteristics were simi-
lar in both treatment arms. Approximately half of the 
patients were men and the mean age was 64 years. For 
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the purpose of the present study, timing of the antihy-
pertensive response was set at 2 months; in both groups 
the median length of the study drug therapy was 61 days 
(range: 47–79 days in the atenolol group and 45–78 days 
in the losartan group) and 57% of the patients were 
using hydrochlorothiazide at the 2-month visit. In the 
atenolol group, mean baseline BP was 171/99 mmHg 
and the mean BP response was -16.4/-10.7 mmHg, 
while in the losartan group the corresponding figures 
were 171/98 mmHg and -16.5/-8.4 mmHg. The most 
noticeable differences between the GENRES and the 
LIFE study subjects at baseline are higher age, higher BP 
level (which is placebo level in GENRES) and  inclusion 
of women in the LIFE study.
Replication analysis of BP response to losartan
Table 2 shows the p-values from the linear regression 
analysis of the BP response to losartan in the LIFE 
study. Of the three SNPs (rs3814995, rs4953045 and 
rs12814605) that showed the strongest associations with 
losartan response in the GENRES study, rs3814995 on 
chromosome 19 was associated with DBP response to 
losartan (β = -0.9 mmHg; p = 0.04; proportion of varia-
tion in the BP response residual explained: 0.009) with 
the same direction of effect in the LIFE study (Figure 1). 
For SBP response, the effect was in the same direction, 
but the association was not statistically significant. In 
patients using losartan 50 mg as monotherapy, the 
associations were similar (n = 199; β = -1.3 mmHg, 
p = 0.21 for SBP response and β = -0.9 mmHg, p = 0.13 
for DBP response). According to Ensembl database 
(www.ensembl.org) rs3814995 is located in the exon 3 
of the NPHS1 gene in chromosome 19 coding for the 
glomerular protein nephrin and is predicted to cause 
an amino acid substitution of glutamic acid to lysine 
(p.Glu117Lys). The other two SNPs did not show sta-
tistically significant replication. SNP–sex interactions 
were not significant for any of the tested SNPs.
Replication analysis of BP response to atenolol
To validate the four SNPs (rs2514036, rs7984003, 
rs7268800 and rs2765115) that showed association 
with bisoprolol response in the GENRES study, we 
tested for their associations with atenolol response in 
LIFE. Table 3 shows the p-values from the linear regres-
sion analysis of the BP response to atenolol. rs2514036, 
achieving genome-wide significance (p = 2 × 10-8) in 
GENRES, associated with systolic (β = -5.5 mmHg; 
p = 0.005; proportion of variation in the BP response 
residual explained: 0.04) and diastolic (β = -1.9 mmHg; 
Table 1. Clinical characteristics of study participants.
Parameter  LIFE participants GENRES participants
 Atenolol Losartan Bisoprolol Losartan
n 467 460 207 202
Age (years) 64 ± 6.2 64 ± 6.2 51 ± 6.2* 51 ± 6.3*
Men (%) 47 49 100* 100*
At baseline
BMI (kg/m2) 27.6 ± 3.6 27.9 ± 3.6 26.7 ± 2.7* 26.6 ± 2.8*
Office SBP (mmHg) 171 ± 14 171 ± 14 152 ± 13* 152 ± 13*
Office DBP (mmHg) 99 ± 7 98 ± 8 100 ± 7 100 ± 7*
Ambulatory 24-h SBP (mmHg) NA NA 135 ± 10 135 ± 10
Ambulatory 24-h DBP (mmHg) NA NA 93 ± 6 93 ± 5
Current smoker (%) 10 10 15* 16*
Serum creatinine (μmol/l) 81 ± 13 81 ± 14 86 ± 13* 86 ± 13*
At 2 months (LIFE)/4 weeks (GENRES)
Δ Office SBP (mmHg) -16.4 ± 14.8 -16.5 ± 13.9 -12.9 ± 10.7* -9.2 ± 12.0*
Δ Office DBP (mmHg) -10.7 ± 10.0 -8.4 ± 7.9 -9.7 ± 7.2 -7.3 ± 6.9
Δ Ambulatory 24-h SBP (mmHg) NA NA -11.1 ± 6.2 -9.1 ± 6.7
Δ Ambulatory 24-h DBP (mmHg) NA NA -8.3 ± 4.2 -6.1 ± 4.7
On hydrochlorothiazide (%) 57 57 0* 0*
Duration of treatment (days) 61 (47–79) 61 (45–78) 30 (27–56)* 30 (27–46)*
Values are presented as mean ± standard deviation, except for percent. Duration of treatment is presented as median and absolute range.
*p < 0.05 compared with LIFE participants.
DBP: Diastolic blood pressure; NA: Not available; SBP: Systolic blood pressure.
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p = 0.05; proportion of variation in the BP response 
residual explained: 0.02) BP response to atenolol in 
men of the LIFE study, with the effect in the same 
direction as in GENRES (Figure 2). When women 
were included in the analysis, the association was no 
longer statistically significant, but the effect was still in 
the same direction. In patients with atenolol 50 mg as 
monotherapy at 2 months, a corresponding association 
was found for SBP response in both men and women 
(n = 201; β = -3.6 mmHg; p = 0.04) and in men only 
(n = 105; β = -4.0 mmHg; p = 0.13). The other three 
SNPs tested did not show a statistically significant rep-
lication. According to Ensembl database, rs2514036 
(base variation G/A) corresponds exactly to the second 
transcription initiation site of the ACY3 gene, coding 
for ACY3, which is known to deacetylate mercapturic 
acids and N-acetyl aromatic amino acids [22].
Metabolic phenotypes related to ACY3 
polymorphism & beta-blocker responses
The fact that we were able to replicate the significant 
association of the rs2514036 (present in the ACY3 
gene) with bisoprolol responses in GENRES to the 
atenolol responses in LIFE prompted us to carry out 
an analysis of the levels and drug responses of certain 
aromatic amino acids relevant to ACY3 action. We 
have carried out a comprehensive metabolic profiling 
using ultra high-performance LC–MS/MS (data to be 
presented in detail in a separate report) in 175 plasma 
samples available from 35 patients in GENRES, using 
bisoprolol as the beta-blocker. In the present study, we 
restricted our analysis on the compounds N-acetyl-
phenylalanine and N-acetyltyrosine, and their deace-
tylated products (derived by ACY3 enzyme action) 
 phenylalanine and tyrosine, respectively [22].
We found a significant inverse correlation between 
the ambulatory DBP (but not SBP) level on placebo, 
and baseline concentrations of plasma phenylala-
nine (r = -0.56; p = 0.0005) and tyrosine (r = -0.47; 
p = 0.003) (Figure 3). In addition, the SBP and DBP 
responses to bisoprolol were significantly correlated to 
the plasma baseline (placebo) levels of phenylalanine 
(p = 0.03 and 0.0005, respectively) and N-acetylphenyl-
alanine (p = 0.0009 and 0.01, respectively) (Figure 4); 
the correlations were in the same direction but weaker 
for plasma tyrosine (p = 0.06 and 0.05, respectively) 
and N-acetyltyrosine (p = 0.22 and 0.38, respectively).
In addition, the plasma concentrations of these com-
pounds increased slightly upon bisoprolol administra-
tion (Supplementary Figure 2); there was no relation 
between these changes and antihypertensive responses 
to bisoprolol (data not shown).
Recently, Yu et al. [23] reported a genome-wide sig-
nificant association of rs12288023, another SNP of the T
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Figure 1. Blood pressure response to losartan by 
genotype for rs3814995 in NPHS1 on chromosome 
19 in the discovery cohort (GENRES) and replication 
study (LIFE). The number of subjects in each genotype 
is shown at the top. Blood pressure responses are 
adjusted for significant covariates as described in 
the ‘Patients & methods’ section. Error bars indicate 
standard error of means. 
DBP: Diastolic blood pressure; SBP: Systolic blood 
pressure.
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ACY3 gene, with serum N-acetylphenylalanine levels 
(p = 9 × 10-15; n = 15,700 subjects). This SNP is in link-
age disequilibrium with rs2514036 (r2 = 0.50), as studied 
in Finns of the 1000 Genomes Project [24]. We studied 
rs12288023 by imputation in GENRES (imputation 
quality, r2 = 0.97) and found that it was associated with 
SBP and DBP responses to bisoprolol (p = 3.1 × 10-5 
and 3.4 × 10-5, respectively) and modestly with placebo 
plasma N-acetylphenylalanine levels (p = 0.24), simi-
lar to our top SNP in GENRES, rs2514036 (p = 0.17) 
(Supplementary Figure 3). The association of the dif-
ferent rs2514036 genotypes with both N-acetylphenyl-
alanine placebo level and SBP response to bisoprolol is 
illustrated in Supplementary Figure 4.
Discussion
The present combined pharmacogenomic study pro-
vides additional evidence for two gene loci influenc-
ing responsiveness to antihypertensive drugs, one locus 
for beta-blockers and another for angiotensin recep-
tor antagonists. We used the GENRES study as our 
primary data set because it has been designed for the 
particular purpose of pharmacogenomic analysis. The 
nature of GENRES as a randomized, double-blind 
and monotherapy-rotational study makes it an almost 
ideal platform to generate hypotheses, with the inevi-
table limitation of its sample size. We had only moder-
ate success in our attempts to replicate GENRES data 
in materials from USA and Italy [10], which prompted 
us to pick up a replication sample from our own pop-
ulation. In fact, due to a variety of reasons, includ-
ing its geographical position, historical population 
bottlenecks and linguistic borders, Finns are consid-
ered to represent a population markedly distinct from 
other western populations in their genetic terms [25]. 
Although this is in particular true for the presence or 
absence of rare gene mutations, it may also influence 
studies on common genetic variants.
The present replication study carried out in the 
LIFE material strengthens our previous evidence of 
the association of rs3814995 with losartan respon-
siveness in hypertensive patients. Accordingly, hyper-
tensive patients carrying the A allele (corresponding to 
lysine) of rs3814995 are more likely to have favorable 
response to losartan compared with those carrying the 
G allele (corresponding to glutamic acid). In the ini-
tial GWAS, the association of rs3814995 with losartan 
response showed replication in two populations; the 
GERA II study (p = 0.03/0.02 for SBP/DBP responses) 
and the SOPHIA study (p = 0.19/0.03 for SBP/DBP 
response) [10]. This makes LIFE study the fourth 
independent population to show a similar associa-
tion. In contrast, the two other SNPs (rs4953045 and 
rs12814605) did not show any significant  association 
with losartan responses in LIFE.
rs3814995 is a missense variant in the coding region 
of NPHS1 gene on chromosome 19q13.12, causing the 
substitution of glutamic acid to lysine (p.Glu117Lys) in 
nephrin, the principal structural protein of the glomer-
ular podocytes [26]. Structure databases PolyPhen2 [27] 
and SIFT [28] predict this alteration to be probably 
damaging. Linkage analysis of GENRES GWAS 
data (Supplementary Figure 5) points to NPHS1 as the 
causal gene. As cited before [10], specific mutations of 
NPHS1 are known to cause the congenital nephrotic 
syndrome of the Finnish type (for review, see [29]). 
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There is increasing evidence from laboratory animals 
and some data from human experimental models to 
link nephrin, angiotensin and angiotensin recep-
tor antagonists together. Thus, in a hypertensive rat 
model, angiotensin II was found to decrease nephrin 
gene expression [30], while irbesartan [31], valsartan [32] 
and losartan [33] have all been shown to counteract 
the decrease of nephrin levels in diabetic hypertensive 
rats. Furthermore, candesartan was found to abolish 
stretch-induced nephrin downregulation in cultured 
human glomerular podocytes [34]. There appear to 
be only few data on the possible clinical significance 
of the Glu117Lys variation. When studying patients 
with diabetic proteinuria, Pettersson-Fernholm et al. 
noticed that carriers of the Lys117 allele had a later 
onset of diabetes than its noncarriers [35]. Summa-
rizing, there is increasing evidence, derived from the 
present study and a combination of three other stud-
ies (GENRES, GERA II and SOPHIA) [10] that the 
nephrin Glu117Lys variation serves as a marker of the 
antihypertensive response of angiotensin II receptor 
blockers. In the present study, Lys117Lys homozygotes 
showed 2–6 mmHg stronger SBP and 2–3 mmHg 
stronger DBP reductions than the Glu117Glu homo-
zygotes (Figure 1). Any  underlying mechanism remains, 
 however, to be investigated.
The other principal finding of the present study was 
the replication of the association of rs2514036 variation 
with beta-blocker response in Finns; this association 
was initially discovered in GENRES comprising men 
only and was subsequently confirmed in LIFE, and 
here principally in men. Accordingly, hetero zygous AG 
men showed approximately 5 mmHg greater reduction 
in SBP and 2–3 mmHg greater reduction in DBP com-
pared with the AA homozygotes in response to biso-
prolol or atenolol administration; the single GG homo-
zygote men in GENRES showed even greater responses 
(Figure 2); there were no GG homozygote men in 
LIFE. It is of note that this association of rs2514036 
with beta-blocker responses could not be replicated in 
the North American population sample of the PEAR 
study [10]. However, sex- dependent metabolic effects of 
atenolol responsiveness were also revealed in the PEAR 
study: in atenolol-treated subjects, development of 
impaired fasting glucose was associated with baseline 
plasma phenylalanine levels in men [36].
According to Ensembl database rs2514036 is a 
5′-variant of the ACY3 gene in chromosome 11q13.2. 
In GENRES GWAS data, the SNPs with the low-
est p-values are located in ACY3 and are also in high 
linkage disequilibrium with the top SNP rs2514036 
(Supplementary Figure 6). According to Ensembl data-
base, ACY3 encodes two different transcript variants, 
ACY3-001 consisting of 8 exons and ACY3-002 con- T
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Figure 2. Blood pressure response to bisoprolol in the discovery cohort (GENRES) and atenolol in the replication 
study (LIFE) by genotype for rs2514036 in ACY3 on chromosome 11. The number of subjects in each genotype is 
shown at the top. Blood pressure responses are adjusted for significant covariates as described in the ‘Patients & 
methods’ section. Error bars indicate standard error of means. 
DBP: Diastolic blood pressure; SBP: Systolic blood pressure.
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sisting of 7 exons. The protein product of transcript 
001 contains 319 amino acids while the protein from 
transcript 002 is shorter, consisting of 198 amino acids. 
Interestingly, rs2514036 hits exactly the transcription 
initiation site of ACY-002. The nucleotide change from 
the wild-type A–G changes a Forkhead box (Fox) tran-
scription factor family DNA-binding domain sequence 
(reviewed in [37]) from ATAAATA to ATGAATA, thus 
possibly affecting ACY3 expression.
A search of publicly available gene expression 
data sets for SNPs associated with ACY3 expres-
sion showed further evidence for this locus. First, in 
the in the Geno type-Tissue Expression database [38], 
rs2514036 was strongly associated with ACY3 expres-
sion (p = 1.8 × 10-20 in meta-analysis of all available 
37 tissues, each with more than 70 analyzed sam-
ples) [39]. Second, rs4313593 23 kb upstream from 
rs2514036 (r2 = 0.50; D´ = 1.00 in Finnish 1000 
Genomes population) was associated with ACY3 
expression (p = 1.3 × 10-7) in lymphoblastoid cell lines 
of the MRCE data set (n = 550) [40,41]. This SNP was 
imputed in GENRES and was associated with both 
systolic (β = -5.4 mmHg; p = 3.1 × 10-5) and diastolic 
(β = -3.6 mmHg; p = 5.1 × 10-5) bisoprolol responses. 
Third, rs2514036 was associated with ACY3 expres-
sion (p = 3.5 × 10-3, combined result of ten regions of 
the brain) in the Braineac database [42,43], and, last, in 
173 ileal biopsy specimen (p = 9.3 × 10-8) [44].
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Figure 3. Association of plasma phenylalanine and tyrosine levels with ambulatory blood pressure level in 
GENRES subjects on placebo. (A) SBP; (B) DBP. Blood pressure levels and normalized metabolite levels are 
presented as covariate-adjusted residuals that were calculated as described in the ‘Patients & methods’ section. 
DBP: Diastolic blood pressure; SBP: Systolic blood pressure.
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ACY3 encodes aminoacylase 3, an enzyme deacety-
lating mercapturic acids and N-acetylated aromatic 
amino acids and, as studied in mouse tissues, its high-
est expression is found in the kidney, followed by liver, 
heart and brain [22]. In humans, ACY3 expression has 
been shown in neurons and adrenal medulla [45]. Mer-
capturic acids are condensation products formed by 
coupling of cysteine with aromatic compounds and are 
considered to represent useful markers of exposure to 
exogenous industrial chemicals; they do not appear to 
show any obvious connection to human hyper tension 
and its drug treatment. In contrast, there is alluring evi-
dence linking ACY3 and aromatic amino acid metabo-
lism to regulation of blood pressure. First, as cited 
above, the tissue-specific expression pattern of ACY3 
is compatible with its potential role in blood pressure 
regulation. Second, its ability to deacetylate N-acetyl-
phenylalanine to phenylalanine and N-acetyltyrosine 
to tyrosine [46] could link this enzyme to the synthesis 
chain of catecholamines. Third, in the present study 
we report a significant correlation between the SBP 
and DBP responses to bisoprolol and pretreatment 
(placebo) plasma levels of phenylalanine and N-acetyl-
phenylalanine (Figure 4). Last, serum phenylalanine 
level as such has been associated with increased cardio-
vascular risk: a prospective study in three population-
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Figure 4. Association of placebo plasma phenylalanine and N-acetylphenylalanine levels with ambulatory blood 
pressure response to bisoprolol in GENRES patients. (A) SBP response; (B) DBP response. Blood pressure responses 
and normalized metabolite levels are presented as covariate-adjusted residuals that were calculated as described 
in the ‘Patients & methods’ section. 
DBP: Diastolic blood pressure; SBP: Systolic blood pressure. 
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based cohorts showed that higher serum phenylalanine 
level was associated with 18% increased cardiovascular 
risk upon long-term follow-up [47], and elevated serum 
phenylalanine concentrations have also been linked to 
increased risk of Type 2 diabetes mellitus [48–50], as well 
as pre-eclampsia [51].
The present study is not without certain important 
limitations. First, when analyzing GENRES data we 
have systematically used ambulatory BP measurements, 
due to their better repeatability (lower coeffi cient of 
variation) compared with office BP measurements [14], 
while we were obliged to use the latter technique in 
the LIFE study. Second, the GENRES study was con-
ducted in men only whereas both sexes were almost 
equally represented in LIFE. Third, while losartan 
was used in both GENRES and LIFE, we compared 
bisoprolol in GENRES with atenolol in LIFE. Fourth, 
approximately half of the LIFE participants were also 
using small doses of thiazide diuretics. However, in the 
monotherapy groups, the observed associations were 
similar, albeit less significant due to lower numbers of 
subjects. Fifth, according to inclusion criteria of LIFE, 
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these patients had high-risk hypertension with elec-
trocardiographic evidence of LVH, while GENRES 
patients had uncomplicated hypertension. All these lim-
itations listed above may play a role in lack of replication 
of some of the positive SNPs (revealed in GENRES) in 
the LIFE material. Sixth and last, the replication results 
of rs3814995 in LIFE (losartan arm) met the nominal 
p-value limit of <0.05 but not the Bonferroni-corrected 
limit of <0.014. We consider this, however, a positive 
replication because the analysis was directed to the 
 previous evidence from three different studies.
Conclusion
We have carried out a replication study of the most 
significant genomic associations of beta-blocker and 
angiotensin II receptor antagonist responses initially 
revealed in the GENRES study [10], using the cor-
responding data in the LIFE study. In both stud-
ies, hypertensive patients of Finnish origin only were 
investigated. Our data provide strengthening evidence 
for the ACY3 gene variation as a biomarker of beta-
blocker responsiveness and the NPHS1 gene variation 
as a marker of angiotensin II type 1 receptor antagonist 
responsiveness. We took the advantage of performing 
these analyses in a genetically homogeneous popula-
tion in order to decrease noise possibly caused by major 
ancestral differences of the patients. It remains to be 
shown, however, whether the data can be generalized 
to other populations, even if we had pre-existing infor-
mation from GENRES suggesting positive replication 
of nephrin variation and losartan responses in other 
populations. The genotype-related differences in SBP 
(2–7 mmHg) and DBP (2–3 mmHg) responses found 
in the present study should be sufficient to be taken into 
account in personalized attempts to decrease the risk of 
cardiovascular mortality of hypertensive patients [10,52].
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Executive summary
Aim
•	 This study was undertaken to replicate and extend the positive genome-wide associations of the 
antihypertensive effects of a beta-blocker (bisoprolol) and an angiotensin receptor antagonist (losartan) in 
the GENRES study, using the Finnish arm of the LIFE study.
Replication analysis of blood pressure response to losartan
•	 NPHS1 (encoding the kidney protein nephrin) variation rs3814995 (Glu117Lys) was associated with the 
antihypertensive effect of losartan in the LIFE study (diastolic blood pressure [BP] change, p = 0.04), 
supporting the initial findings in the GENRES, GERA II and SOPHIA studies.
Replication analysis of BP response to atenolol
•	 ACY3 (encoding for aminoacylase 3) variation rs2514036 was associated with systolic (p = 0.005) and diastolic 
(p = 0.05) BP responses to atenolol in men of the LIFE study, supporting the genome-wide significant 
association (p = 2 × 10-8) obtained from the GENRES study, which included only men.
•	 eQTL data in four different databases show strong association of rs2514036 with ACY3 expression in several 
tissues.
Metabolic phenotypes related to ACY3 polymorphism & beta-blocker responses
•	 The plasma concentrations of the substrate (N-acetylphenylalanine) and the end product 
(acetylphenylalanine, a precursor of catecholamines) of ACY3 action were analyzed in GENRES.
•	 Systolic and diastolic BP responses to bisoprolol were significantly correlated to the plasma baseline (placebo) 
levels of phenylalanine (p = 0.03 and 0.0005, respectively) and N-acetylphenylalanine (p = 0.0009 and 0.01, 
respectively) in GENRES.
Conclusion
•	 The results strengthen the evidence for the ACY3 variation rs2514036 as a biomarker of beta-blocker 
responsiveness and the NPHS1 variation rs3814995 as a marker of angiotensin II type 1 receptor antagonist 
responsiveness.
•	 The plasma concentrations of N-acetylphenylalanine and phenylalanine, ACY3-related catecholamine 
synthesis precursors, may predict the antihypertensive response to beta-blockers.
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